The PRT product line facilitates precise toner coloration through superior dispersion, ease of handling and dosing when compared to traditional powders.

This sulfone line of masterbatches can accommodate a range of high-temperature application needs.

History proves that when supply gets tight, small plastisol producers can be the last in line to receive resin.

Natural grades can be colored during processing with compatible products from Avient’s OnColor™ color concentrate line

ATO has also been found to be useful as a catalyst for PET manufacture, as a frictional additive in automotive brake linings, as a clarifier for glass, as an opacifier for enamels, as a coating for titanium dioxide applications, and as a stabilizer for certain pigments.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 26 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 3 2 2 2 3 3 4 3 3 3 4 4 5 5 5 6 7 7 8 24 t (E xc l. D is t. ) LB Median: 5%Median: 3% Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Other Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. We will deliver for our stakeholders through multiple value creation levers—many of which are unique to Avient: o Demand for sustainable solutions, healthcare, and composites, together with Clariant Masterbatch revenue synergies, that will drive 2021 revenue growth of 14% and long-term growth in excess of GDP o Clariant Masterbatch cost synergy capture will result in significant near-term benefit In addition, we remain committed to increasing annual dividends in line with earnings growth and opportunistically buying back shares, all while remaining modestly levered.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 30 Capex / Revenue 2022E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 4 7 7 7 ( xc l. Avient reflects 2022 estimated revenue of $5,100M and estimated CAPEX of $90M (excludes IT system upgrade of $25M and synergy capture CAPEX of $20M) Avient Specialty Other Free Cash Flow Conversion (1) 2022E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. We will deliver for our stakeholders through multiple value creation levers—many of which are unique to Avient: o Demand for sustainable solutions, healthcare, and composites, together with Clariant Color revenue synergies, that will drive long-term revenue growth in excess of GDP o Clariant color cost synergy capture will result in significant near-term benefit In addition, we remain committed to increasing annual dividends in line with earnings growth and opportunistically buying back shares, all while remaining modestly levered.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 24 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 3 2 2 3 3 3 4 3 3 4 4 4 5 5 5 5 7 7 8 23 t (E xc l. D is t. ) LB Median: 5%Median: 3% Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Other Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. We will deliver for our stakeholders through multiple value creation levers—many of which are unique to Avient: o Demand for sustainable solutions, healthcare, and composites, together with Clariant Masterbatch revenue synergies, that will drive 2021 revenue growth of 8% and long-term growth in excess of GDP o Clariant Masterbatch cost synergy capture will result in significant near-term benefit In addition, we remain committed to increasing annual dividends in line with earnings growth and opportunistically buying back shares, all while remaining modestly levered.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 3 2 2 2 3 3 3 4 4 5 5 5 6 6 6 7 9 25 t (E xc l. D is t. ) LB Median: 5%Median: 3% Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Other Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. We will deliver for our stakeholders through multiple value creation levers—many of which are unique to Avient: o Demand for sustainable solutions, healthcare, and composites, together with Clariant Masterbatch revenue synergies, that will drive 2021 revenue growth of 8% and long-term growth in excess of GDP o Clariant Masterbatch cost synergy capture will result in significant near-term benefit In addition, we remain committed to increasing annual dividends in line with earnings growth and opportunistically buying back shares, all while remaining modestly levered.

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 26 Capex / Revenue 2022E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 7 7 ( xc l. Avient reflects 2022 estimated revenue of $5,100M and estimated CAPEX of $90M (excludes IT system upgrade of $25M and synergy capture CAPEX of $20M) Avient Specialty Other Free Cash Flow Conversion (1) 2022E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. We will deliver for our stakeholders through multiple value creation levers—many of which are unique to Avient: o Demand for sustainable solutions, healthcare, and composites, together with Clariant Color revenue synergies, that will drive long-term revenue growth in excess of GDP o Clariant color cost synergy capture will result in significant near-term benefit In addition, we remain committed to increasing annual dividends in line with earnings growth and opportunistically buying back shares, all while remaining modestly levered.